฿205.56
-฿1.13(-0.54%)
data.updated
v2.stock.overview v2.daily.trading v2.range.52w
key.stats
yesterday.close฿206.69
market.size฿357.03B
volume.trade1.07M
pe.ratio96.81
div.yield3.29%
div.amount฿1.73
diluted.eps2.37
net.income฿4.22B
revenue฿61.16B
earnings.date2026-04-29
eps.estimate3.01
rev.estimate฿14.71B
shares.out1.72B
beta0.364
ex.div.date2026-04-15
div.pay.date2026-05-15
about.stock
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
sectorHealthcare
industryDrug Manufacturers - General
ceoScott T. Reents
headquartersNorth Chicago,IL,US
websitehttps://www.abbvie.com
employees57.00K
avg.revenue฿1.07M
income.per.emp฿74.14K
stock.faq
stock.price
x
current.stats
52w.range.q
x
pe.ratio.q
x
market.cap.q
x
eps.recent.q
x
buy.sell.q
x
price.factors
x
buy.how
x
risk.warn
risk.notice
disclaimer2
risk.disclosure






















































































































































































































































